公开(公告)号：US08114869B2

公开(公告)日：2012-02-14

申请号：US13106494

申请日：2011-05-12

申请人： Marc Sadler Tesconi ,  Mannching Sherry Ku ,  Yan Xu

发明人： Marc Sadler Tesconi ,  Mannching Sherry Ku ,  Yan Xu

IPC分类号： A61K31/536 ,  A61P15/18 ,  C07D265/18

CPC分类号： C07D413/04 ,  C07D265/18 ,  C07B2200/13

摘要： Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Form II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating or preventing uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, or carcinomas and adenocarcinomas comprising administering polymorph Form II to a mammalian subject.

摘要翻译： Tanaproget多晶型物II，制备tanaproget多晶型II的方法，包括tanaproget多晶型II，微粉化tanaproget多晶型II的药物组合物，以及将II型转化成tanaproget形式I的方法。 还提供了避孕，激素替代疗法，刺激食物摄取和治疗或预防子宫肌层肌瘤，良性前列腺肥大，良性和恶性肿瘤性疾病，功能障碍性出血，子宫平滑肌瘤，子宫内膜异位症，多囊卵巢综合征或癌和腺癌的方法，包括 向哺乳动物受试者施用多晶型II。

公开(公告)号：US20110212953A1

公开(公告)日：2011-09-01

申请号：US13106494

申请日：2011-05-12

申请人： Marc Sadler Tesconi ,  Mannching Sherry Ku ,  Yan Xu

发明人： Marc Sadler Tesconi ,  Mannching Sherry Ku ,  Yan Xu

IPC分类号： A61K31/536 ,  C07D413/04 ,  A61P15/18 ,  A61P5/00 ,  A61P3/00 ,  A61P35/00 ,  A61P7/00 ,  A61P15/00

CPC分类号： C07D413/04 ,  C07D265/18 ,  C07B2200/13

摘要： Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Form II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating or preventing uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, or carcinomas and adenocarcinomas comprising administering polymorph Form II to a mammalian subject.

摘要翻译： Tanaproget多晶型物II，制备tanaproget多晶型II的方法，包括tanaproget多晶型II，微粉化tanaproget多晶型II的药物组合物，以及将II型转化成tanaproget形式I的方法。 还提供了避孕，激素替代疗法，刺激食物摄取和治疗或预防子宫肌层肌瘤，良性前列腺肥大，良性和恶性肿瘤性疾病，功能障碍性出血，子宫平滑肌瘤，子宫内膜异位症，多囊卵巢综合征或癌和腺癌的方法，包括 向哺乳动物受试者施用多晶型II。

公开(公告)号：US07968709B2

公开(公告)日：2011-06-28

申请号：US12792978

申请日：2010-06-03

申请人： Marc Sadler Tesconi ,  Mannching Sherry Ku ,  Yan Xu

发明人： Marc Sadler Tesconi ,  Mannching Sherry Ku ,  Yan Xu

IPC分类号： C07D265/18

CPC分类号： C07D413/04 ,  C07D265/18 ,  C07B2200/13

摘要： Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Form II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating or preventing uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, or carcinomas and adenocarcinomas comprising administering polymorph Form II to a mammalian subject.

摘要翻译： Tanaproget多晶型物II，制备tanaproget多晶型II的方法，包括tanaproget多晶型II，微粉化tanaproget多晶型II的药物组合物，以及将II型转化成tanaproget形式I的方法。 还提供了避孕，激素替代疗法，刺激食物摄取和治疗或预防子宫肌层肌瘤，良性前列腺肥大，良性和恶性肿瘤性疾病，功能障碍性出血，子宫平滑肌瘤，子宫内膜异位症，多囊卵巢综合征或癌和腺癌的方法，包括 向哺乳动物受试者施用多晶型II。

公开(公告)号：US07759341B2

公开(公告)日：2010-07-20

申请号：US11412015

申请日：2006-04-26

申请人： Marc Sadler Tesconi ,  Mannching Sherry Ku ,  Yan Xu

发明人： Marc Sadler Tesconi ,  Mannching Sherry Ku ,  Yan Xu

IPC分类号： A61K31/536

CPC分类号： C07D413/04 ,  C07D265/18 ,  C07B2200/13

摘要： Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Form II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating or preventing uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, or carcinomas and adenocarcinomas comprising administering polymorph Form II to a mammalian subject.

摘要翻译： Tanaproget多晶型物II，制备tanaproget多晶型II的方法，包括tanaproget多晶型II，微粉化tanaproget多晶型II的药物组合物，以及将II型转化成tanaproget形式I的方法。 还提供了避孕，激素替代疗法，刺激食物摄取和治疗或预防子宫肌层肌瘤，良性前列腺肥大，良性和恶性肿瘤性疾病，功能障碍性出血，子宫平滑肌瘤，子宫内膜异位症，多囊卵巢综合征或癌和腺癌的方法，包括 向哺乳动物受试者施用多晶型II。

公开(公告)号：US20120115858A1

公开(公告)日：2012-05-10

申请号：US13347080

申请日：2012-01-10

申请人： Marc Sadler Tesconi ,  Mannching Sherry Ku ,  Yan Xu

发明人： Marc Sadler Tesconi ,  Mannching Sherry Ku ,  Yan Xu

IPC分类号： A61K31/536 ,  A61P5/24 ,  A61P7/04 ,  A61P13/08 ,  A61P35/00 ,  C07D265/18 ,  A61P15/00

CPC分类号： C07D413/04 ,  C07D265/18 ,  C07B2200/13

摘要： Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Form II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating or preventing uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, or carcinomas and adenocarcinomas comprising administering polymorph Form II to a mammalian subject.

摘要翻译： Tanaproget多晶型物II，制备tanaproget多晶型II的方法，包括tanaproget多晶型II，微粉化tanaproget多晶型II的药物组合物，以及将II型转化成tanaproget形式I的方法。 还提供了避孕，激素替代疗法，刺激食物摄取和治疗或预防子宫肌层肌瘤，良性前列腺肥大，良性和恶性肿瘤性疾病，功能障碍性出血，子宫平滑肌瘤，子宫内膜异位症，多囊卵巢综合征或癌和腺癌的方法，包括 向哺乳动物受试者施用多晶型II。

公开(公告)号：US20100267715A1

公开(公告)日：2010-10-21

申请号：US12792978

申请日：2010-06-03

申请人： Marc Sadler Tesconi ,  Mannching Sherry Ku ,  Yan Xu

发明人： Marc Sadler Tesconi ,  Mannching Sherry Ku ,  Yan Xu

IPC分类号： A61K31/536 ,  C07D265/18 ,  A61P35/00 ,  A61P15/18 ,  A61P1/14

CPC分类号： C07D413/04 ,  C07D265/18 ,  C07B2200/13

摘要： Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Form II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating or preventing uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, or carcinomas and adenocarcinomas comprising administering polymorph Form II to a mammalian subject.

摘要翻译： Tanaproget多晶型物II，制备tanaproget多晶型II的方法，包括tanaproget多晶型II，微粉化tanaproget多晶型II的药物组合物，以及将II型转化成tanaproget形式I的方法。 还提供了避孕，激素替代疗法，刺激食物摄取和治疗或预防子宫肌层肌瘤，良性前列腺肥大，良性和恶性肿瘤性疾病，功能障碍性出血，子宫平滑肌瘤，子宫内膜异位症，多囊卵巢综合征或癌和腺癌的方法，包括 向哺乳动物受试者施用多晶型II。

公开(公告)号：US20080188540A1

公开(公告)日：2008-08-07

申请号：US12026300

申请日：2008-02-05

申请人： Marc Sadler Tesconi ,  Mannching Sherry Ku ,  Yan Xu ,  Hsueh-Ling Wu

发明人： Marc Sadler Tesconi ,  Mannching Sherry Ku ,  Yan Xu ,  Hsueh-Ling Wu

IPC分类号： A61K31/40 ,  A61P25/28

CPC分类号： A61K9/107 ,  A61K9/4858 ,  A61K31/4045 ,  A61K47/14 ,  A61K47/26 ,  A61K47/44

摘要： Pharmaceutical compositions containing compounds of formula I are provided: wherein the constituent variables are as defined herein. The compositions are useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1) for treating conditions resulting from fibrinolytic disorders, such as deep vein thrombosis and coronary heart disease, Alzheimer's disease and pulmonary fibrosis.

摘要翻译： 提供了含有式I化合物的药物组合物：其中组成变量如本文所定义。 该组合物可用作纤溶酶原激活物抑制剂-1（PAI-1）的抑制剂，用于治疗由纤维蛋白溶解性疾病如深静脉血栓形成和冠心病，阿尔茨海默氏病和肺纤维化引起的病症。

公开(公告)号：USD950965S1

公开(公告)日：2022-05-10

申请号：US29720973

申请日：2020-01-16

申请人： Yan Xu

设计人： Yan Xu

公开(公告)号：US20170285916A1

公开(公告)日：2017-10-05

申请号：US15085677

申请日：2016-03-30

申请人： Yan Xu ,  Maha El Choubassi ,  Ronald T. Azuma ,  Oscar Nestares

发明人： Yan Xu ,  Maha El Choubassi ,  Ronald T. Azuma ,  Oscar Nestares

IPC分类号： G06F3/0484 ,  G06T11/00 ,  G06T7/00 ,  G06T3/00 ,  G06T5/00

CPC分类号： G06F3/04845 ,  G06F3/04842 ,  G06F3/04883 ,  G06T11/60 ,  G06T2200/04 ,  H04N5/2226 ,  H04N5/2621 ,  H04N5/272 ,  H04N5/445

摘要： Embodiments of a system and method for applying camera effects to an image are generally described herein. A method may include receiving, at a device, information including an image and depth data of pixels of the image, generating a set of candidate regions of interest in the image, receiving a user selection of a region of interest of the set of candidate regions of interest, and generating a camera effect for the image using the region of interest and the depth data. The method may include outputting an augmented image, outputting information, outputting a video, or the like.

公开(公告)号：US09781716B2

公开(公告)日：2017-10-03

申请号：US14238760

申请日：2011-08-15

申请人： Chia Han Siong Samuel ,  Fan Yang ,  Yan Xu ,  Mingjun Chen ,  Jianliang Liu ,  Hong Du

发明人： Chia Han Siong Samuel ,  Fan Yang ,  Yan Xu ,  Mingjun Chen ,  Jianliang Liu ,  Hong Du

IPC分类号： H04W72/04 ,  H04J3/16 ,  H04W72/12 ,  H04W84/08 ,  H04W76/02

CPC分类号： H04W72/0446 ,  H04J3/1694 ,  H04W72/1247 ,  H04W76/14 ,  H04W84/08

摘要： A high priority service sending method and device in a direct mode, and a high priority service receiving method and device in a direct mode. The receiving method includes: after sending a voice frame in a voice call sending state, a user terminal receiving and detecting a priority frame in another time slot with respect to the time slot occupied by the voice call; and if the priority frame is detected, then stopping the voice call and receiving a high priority service frame in the other time slot. Using the present invention can enable an interphone in a transmitting state in a direct mode to send or receive a high priority service as well.